Related Experiment Videos
Evaluation of antiarrhythmic activity of prostaglandin F2 alpha in man
Abstract:
Since prostaglandin (PG) F2 alpha had been shown to act anti-arrhythmically in various animal models and also in preliminary investigations in man, further evaluation of this effect was made in 30 patients with cardiac extrasystoles and in 2 patients with tachycardias. PGF2 alpha was infused intravenously at individually adapted consecutive rates from 5 to 100 micrograms/min each for at least 5 min. In the incidence of extrasystoles a mean maximum decrease of 41% (P less than 0.001) was obtained. One patient showed repeated short interruptions of a ventricular tachycardia. A dose-dependent significant rise in blood pressure and no significant influences on heart rate, PQ interval and QRS interval of the ECG were found. It is concluded that PGF2 alpha has probably no practical importance for the therapy of cardiac arrhythmias.
Insights
Prostaglandin (PG) F2 alpha showed a significant reduction in cardiac extrasystoles but did not prove clinically useful for treating arrhythmias. Further research is needed to explore its therapeutic potential.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Prostaglandin (PG) F2 alpha has demonstrated anti-arrhythmic properties in animal models and preliminary human studies.
- Cardiac arrhythmias, including extrasystoles and tachycardias, represent a significant clinical challenge.
Purpose of the Study:
- To evaluate the anti-arrhythmic effects of intravenous Prostaglandin (PG) F2 alpha in patients with cardiac extrasystoles and tachycardias.
- To assess the safety and efficacy of PGF2 alpha in managing cardiac rhythm disturbances.
Main Methods:
- Intravenous infusion of Prostaglandin (PG) F2 alpha at doses ranging from 5 to 100 micrograms/min in 30 patients with extrasystoles and 2 with tachycardias.
- Monitoring of arrhythmia incidence, blood pressure, heart rate, and electrocardiogram (ECG) intervals (PQ, QRS).
Main Results:
- A significant mean maximum decrease of 41% in extrasystole incidence (P < 0.001) was observed.
- One patient experienced short interruptions of ventricular tachycardia.
- A dose-dependent increase in blood pressure was noted, with no significant changes in heart rate or ECG intervals.
Conclusions:
- Prostaglandin (PG) F2 alpha demonstrated a statistically significant reduction in extrasystoles.
- Despite anti-arrhythmic effects, PGF2 alpha likely holds no practical therapeutic importance for cardiac arrhythmias due to observed side effects and limited efficacy in tachycardias.